Granules India gets USFDA nod of Metformin HCL ER Tablets

Metformin Hydrochloride ER Tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

62
USFDA
Picture: Pixabay

Last Updated on January 16, 2021 by The Health Master

Medicine
Picture: Pixabay

Granules India announced that the US Food & Drug Administration (USFDA) has granted final approval for its Abbreviated New Drug Application (ANDA) for Metformin Hydrochloride Extended-Release Tablets USP, 500 mg and 1000 mg, generic equivalent of Glumetza ER Tablets, 500 mg and 1000 mg, of Bausch Health US.

Metformin Hydrochloride ER Tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Metformin Hydrochloride ER Tablets had US sales of approximately $192 million for the most recent twelve months ending in November 2020 according to IQVIA Health.

Granules now has a total of 35 ANDA approvals from USFDA (34 final approvals and 1 tentative approval). Glumetza is a trademark of Salix Pharmaceuticals or its affiliates.


Also read | Dr Reddys Lab launches generic Uloric Tablets


The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.

Follow and connect with us on Facebook and Linkedin

Go to main website, click here

Subscribe for daily free updates, click here

Subscribe here for daily updates
Loading